Therefore, to find additional markers for the differential diagnosis between type 1 AIP and pancreatic cancer (perhaps IFN-α and IL-33 serum levels) is essential, and will be the focus of our next study. This evidence concerns the gene IL33 and familial pancreatic carcinoma.